Nutritional status and gastroenteropancreatic neuroendocrine neoplasms: lights and shadows with a clinical guide from the NIKE Group

Nutritional status and gastroenteropancreatic neuroendocrine neoplasms: lights and shadows with a clinical guide from the NIKE Group

Neuroendocrine neoplasms (NENs) originating in the gastroenteropancreatic (GEP) tract are rare tumors often associated with significant metabolic disturbances and nutritional challenges. This review explores the intricate relationship between nutritional status and the development, progression, and...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Reviews in endocrine & metabolic disorders 2024-12
Hauptverfasser: Vitale, Giovanni, Gaudenzi, Germano, Oldani, Monica, Pandozzi, Carla, Filice, Alessia, Jaafar, Simona, Barrea, Luigi, Colao, Annamaria, Faggiano, Antongiulio
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title Reviews in endocrine & metabolic disorders
container_volume
creator Vitale, Giovanni
Gaudenzi, Germano
Oldani, Monica
Pandozzi, Carla
Filice, Alessia
Jaafar, Simona
Barrea, Luigi
Colao, Annamaria
Faggiano, Antongiulio
description Neuroendocrine neoplasms (NENs) originating in the gastroenteropancreatic (GEP) tract are rare tumors often associated with significant metabolic disturbances and nutritional challenges. This review explores the intricate relationship between nutritional status and the development, progression, and prognosis of GEP-NENs. Through an extensive literature search encompassing studies up to April 2024, we examined various factors, including obesity, malnutrition, metabolic syndrome and type 2 diabetes mellitus, and their roles in the development and progression of GEP-NENs. The review highlights the dual role of obesity, both as a risk factor and a potential prognostic indicator, drawing attention to the 'obesity paradox' observed in cancer research. Additionally, we discuss the impact of malnutrition on patient outcomes and emphasize the need for comprehensive nutritional assessments beyond BMI. This analysis highlights the importance of incorporating nutritional interventions into preventive and therapeutic strategies for GEP-NEN patients. Future research should further clarify these associations and develop personalized nutritional management protocols to improve patient prognosis and quality of life. Acronyms adopted in the text and tables: AOR: adjusted odd ratio, BIA: Bioelectrical Impedance Analysis, BMI: Body Mass Index, CI: confidence interval, CLARINET: Controlled Study of Lanreotide Antiproliferative Response in Neuroendocrine Tumor, FLI: fatty liver index, GEP: gastroenteropancreatic, GLIM: global leadership into malnutrition, HR: hazard ratio, MS: metabolic syndrome, MUST: malabsorption universal screening tool, NEC: neuroendocrine carcinoma, NENs: Neuroendocrine neoplasms, NETs: Neuroendocrine tumors, NRS: Nutritional Risk Screening, OR: odd ratio, OS: overall survival, PFS: progression-free survival, RR: risk ratio, SGA: Subjective Global Assessment, T2DM: type 2 diabetes mellitus, VAI: visceral adiposity index, WD: well-differentiated.
doi_str_mv 10.1007/s11154-024-09937-2
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3146609409</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3146609409</sourcerecordid><originalsourceid>FETCH-LOGICAL-c184t-371337f228f960b3896ee7a90489ff24bee0c2f32e380ddf6a9c3d387c31379e3</originalsourceid><addsrcrecordid>eNo9kEtv3CAUhVGVqDOZ9g90UbHMxilwbWy6q6K81CjdtGvE4MsMlW1cwIqyzw8P6UyyuLoP3XOk8xHyhbMLzlj7LXHOm7piopRS0FbiA1nzpoVKSCZPygydqhRvmhU5S-kvY4JL1XwkK1CyAdXJNXl-WHL02YfJDDRlk5dEzdTTnUk5BpwyxjCbyUY02Vs64fJ67YONfsKyhnkwaUzf6eB3-3zQpr3pw2Oijz7vqaF28JO3xX63-B6pi2GkeY_04e7nFb2JYZk_kVNnhoSfj31D_lxf_b68re5_3dxd_rivLO_qXEHLAVonROeUZNsSTiK2RrG6U86JeovIrHAgEDrW904aZaGHrrXAoVUIG3J-8J1j-Ldgynr0yeIwmBJkSRp4LSVTNVPlVRxebQwpRXR6jn408Ulzpl_p6wN9Xejr__S1KKKvR_9lO2L_LnnDDS-0IYKb</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3146609409</pqid></control><display><type>article</type><title>Nutritional status and gastroenteropancreatic neuroendocrine neoplasms: lights and shadows with a clinical guide from the NIKE Group</title><source>SpringerLink Journals</source><creator>Vitale, Giovanni ; Gaudenzi, Germano ; Oldani, Monica ; Pandozzi, Carla ; Filice, Alessia ; Jaafar, Simona ; Barrea, Luigi ; Colao, Annamaria ; Faggiano, Antongiulio</creator><creatorcontrib>Vitale, Giovanni ; Gaudenzi, Germano ; Oldani, Monica ; Pandozzi, Carla ; Filice, Alessia ; Jaafar, Simona ; Barrea, Luigi ; Colao, Annamaria ; Faggiano, Antongiulio ; Nike Group</creatorcontrib><description>Neuroendocrine neoplasms (NENs) originating in the gastroenteropancreatic (GEP) tract are rare tumors often associated with significant metabolic disturbances and nutritional challenges. This review explores the intricate relationship between nutritional status and the development, progression, and prognosis of GEP-NENs. Through an extensive literature search encompassing studies up to April 2024, we examined various factors, including obesity, malnutrition, metabolic syndrome and type 2 diabetes mellitus, and their roles in the development and progression of GEP-NENs. The review highlights the dual role of obesity, both as a risk factor and a potential prognostic indicator, drawing attention to the 'obesity paradox' observed in cancer research. Additionally, we discuss the impact of malnutrition on patient outcomes and emphasize the need for comprehensive nutritional assessments beyond BMI. This analysis highlights the importance of incorporating nutritional interventions into preventive and therapeutic strategies for GEP-NEN patients. Future research should further clarify these associations and develop personalized nutritional management protocols to improve patient prognosis and quality of life. Acronyms adopted in the text and tables: AOR: adjusted odd ratio, BIA: Bioelectrical Impedance Analysis, BMI: Body Mass Index, CI: confidence interval, CLARINET: Controlled Study of Lanreotide Antiproliferative Response in Neuroendocrine Tumor, FLI: fatty liver index, GEP: gastroenteropancreatic, GLIM: global leadership into malnutrition, HR: hazard ratio, MS: metabolic syndrome, MUST: malabsorption universal screening tool, NEC: neuroendocrine carcinoma, NENs: Neuroendocrine neoplasms, NETs: Neuroendocrine tumors, NRS: Nutritional Risk Screening, OR: odd ratio, OS: overall survival, PFS: progression-free survival, RR: risk ratio, SGA: Subjective Global Assessment, T2DM: type 2 diabetes mellitus, VAI: visceral adiposity index, WD: well-differentiated.</description><identifier>ISSN: 1389-9155</identifier><identifier>ISSN: 1573-2606</identifier><identifier>EISSN: 1573-2606</identifier><identifier>DOI: 10.1007/s11154-024-09937-2</identifier><identifier>PMID: 39653986</identifier><language>eng</language><publisher>Germany</publisher><ispartof>Reviews in endocrine &amp; metabolic disorders, 2024-12</ispartof><rights>2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c184t-371337f228f960b3896ee7a90489ff24bee0c2f32e380ddf6a9c3d387c31379e3</cites><orcidid>0000-0002-9324-3946 ; 0009-0001-8339-5591 ; 0000-0003-2478-683X ; 0000-0002-1512-8926 ; 0009-0002-6045-2992 ; 0000-0001-9054-456X ; 0000-0003-3516-8471 ; 0000-0002-7427-1431 ; 0000-0003-4049-2559</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39653986$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vitale, Giovanni</creatorcontrib><creatorcontrib>Gaudenzi, Germano</creatorcontrib><creatorcontrib>Oldani, Monica</creatorcontrib><creatorcontrib>Pandozzi, Carla</creatorcontrib><creatorcontrib>Filice, Alessia</creatorcontrib><creatorcontrib>Jaafar, Simona</creatorcontrib><creatorcontrib>Barrea, Luigi</creatorcontrib><creatorcontrib>Colao, Annamaria</creatorcontrib><creatorcontrib>Faggiano, Antongiulio</creatorcontrib><creatorcontrib>Nike Group</creatorcontrib><title>Nutritional status and gastroenteropancreatic neuroendocrine neoplasms: lights and shadows with a clinical guide from the NIKE Group</title><title>Reviews in endocrine &amp; metabolic disorders</title><addtitle>Rev Endocr Metab Disord</addtitle><description>Neuroendocrine neoplasms (NENs) originating in the gastroenteropancreatic (GEP) tract are rare tumors often associated with significant metabolic disturbances and nutritional challenges. This review explores the intricate relationship between nutritional status and the development, progression, and prognosis of GEP-NENs. Through an extensive literature search encompassing studies up to April 2024, we examined various factors, including obesity, malnutrition, metabolic syndrome and type 2 diabetes mellitus, and their roles in the development and progression of GEP-NENs. The review highlights the dual role of obesity, both as a risk factor and a potential prognostic indicator, drawing attention to the 'obesity paradox' observed in cancer research. Additionally, we discuss the impact of malnutrition on patient outcomes and emphasize the need for comprehensive nutritional assessments beyond BMI. This analysis highlights the importance of incorporating nutritional interventions into preventive and therapeutic strategies for GEP-NEN patients. Future research should further clarify these associations and develop personalized nutritional management protocols to improve patient prognosis and quality of life. Acronyms adopted in the text and tables: AOR: adjusted odd ratio, BIA: Bioelectrical Impedance Analysis, BMI: Body Mass Index, CI: confidence interval, CLARINET: Controlled Study of Lanreotide Antiproliferative Response in Neuroendocrine Tumor, FLI: fatty liver index, GEP: gastroenteropancreatic, GLIM: global leadership into malnutrition, HR: hazard ratio, MS: metabolic syndrome, MUST: malabsorption universal screening tool, NEC: neuroendocrine carcinoma, NENs: Neuroendocrine neoplasms, NETs: Neuroendocrine tumors, NRS: Nutritional Risk Screening, OR: odd ratio, OS: overall survival, PFS: progression-free survival, RR: risk ratio, SGA: Subjective Global Assessment, T2DM: type 2 diabetes mellitus, VAI: visceral adiposity index, WD: well-differentiated.</description><issn>1389-9155</issn><issn>1573-2606</issn><issn>1573-2606</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNo9kEtv3CAUhVGVqDOZ9g90UbHMxilwbWy6q6K81CjdtGvE4MsMlW1cwIqyzw8P6UyyuLoP3XOk8xHyhbMLzlj7LXHOm7piopRS0FbiA1nzpoVKSCZPygydqhRvmhU5S-kvY4JL1XwkK1CyAdXJNXl-WHL02YfJDDRlk5dEzdTTnUk5BpwyxjCbyUY02Vs64fJ67YONfsKyhnkwaUzf6eB3-3zQpr3pw2Oijz7vqaF28JO3xX63-B6pi2GkeY_04e7nFb2JYZk_kVNnhoSfj31D_lxf_b68re5_3dxd_rivLO_qXEHLAVonROeUZNsSTiK2RrG6U86JeovIrHAgEDrW904aZaGHrrXAoVUIG3J-8J1j-Ldgynr0yeIwmBJkSRp4LSVTNVPlVRxebQwpRXR6jn408Ulzpl_p6wN9Xejr__S1KKKvR_9lO2L_LnnDDS-0IYKb</recordid><startdate>20241209</startdate><enddate>20241209</enddate><creator>Vitale, Giovanni</creator><creator>Gaudenzi, Germano</creator><creator>Oldani, Monica</creator><creator>Pandozzi, Carla</creator><creator>Filice, Alessia</creator><creator>Jaafar, Simona</creator><creator>Barrea, Luigi</creator><creator>Colao, Annamaria</creator><creator>Faggiano, Antongiulio</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9324-3946</orcidid><orcidid>https://orcid.org/0009-0001-8339-5591</orcidid><orcidid>https://orcid.org/0000-0003-2478-683X</orcidid><orcidid>https://orcid.org/0000-0002-1512-8926</orcidid><orcidid>https://orcid.org/0009-0002-6045-2992</orcidid><orcidid>https://orcid.org/0000-0001-9054-456X</orcidid><orcidid>https://orcid.org/0000-0003-3516-8471</orcidid><orcidid>https://orcid.org/0000-0002-7427-1431</orcidid><orcidid>https://orcid.org/0000-0003-4049-2559</orcidid></search><sort><creationdate>20241209</creationdate><title>Nutritional status and gastroenteropancreatic neuroendocrine neoplasms: lights and shadows with a clinical guide from the NIKE Group</title><author>Vitale, Giovanni ; Gaudenzi, Germano ; Oldani, Monica ; Pandozzi, Carla ; Filice, Alessia ; Jaafar, Simona ; Barrea, Luigi ; Colao, Annamaria ; Faggiano, Antongiulio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c184t-371337f228f960b3896ee7a90489ff24bee0c2f32e380ddf6a9c3d387c31379e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vitale, Giovanni</creatorcontrib><creatorcontrib>Gaudenzi, Germano</creatorcontrib><creatorcontrib>Oldani, Monica</creatorcontrib><creatorcontrib>Pandozzi, Carla</creatorcontrib><creatorcontrib>Filice, Alessia</creatorcontrib><creatorcontrib>Jaafar, Simona</creatorcontrib><creatorcontrib>Barrea, Luigi</creatorcontrib><creatorcontrib>Colao, Annamaria</creatorcontrib><creatorcontrib>Faggiano, Antongiulio</creatorcontrib><creatorcontrib>Nike Group</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Reviews in endocrine &amp; metabolic disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vitale, Giovanni</au><au>Gaudenzi, Germano</au><au>Oldani, Monica</au><au>Pandozzi, Carla</au><au>Filice, Alessia</au><au>Jaafar, Simona</au><au>Barrea, Luigi</au><au>Colao, Annamaria</au><au>Faggiano, Antongiulio</au><aucorp>Nike Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nutritional status and gastroenteropancreatic neuroendocrine neoplasms: lights and shadows with a clinical guide from the NIKE Group</atitle><jtitle>Reviews in endocrine &amp; metabolic disorders</jtitle><addtitle>Rev Endocr Metab Disord</addtitle><date>2024-12-09</date><risdate>2024</risdate><issn>1389-9155</issn><issn>1573-2606</issn><eissn>1573-2606</eissn><abstract>Neuroendocrine neoplasms (NENs) originating in the gastroenteropancreatic (GEP) tract are rare tumors often associated with significant metabolic disturbances and nutritional challenges. This review explores the intricate relationship between nutritional status and the development, progression, and prognosis of GEP-NENs. Through an extensive literature search encompassing studies up to April 2024, we examined various factors, including obesity, malnutrition, metabolic syndrome and type 2 diabetes mellitus, and their roles in the development and progression of GEP-NENs. The review highlights the dual role of obesity, both as a risk factor and a potential prognostic indicator, drawing attention to the 'obesity paradox' observed in cancer research. Additionally, we discuss the impact of malnutrition on patient outcomes and emphasize the need for comprehensive nutritional assessments beyond BMI. This analysis highlights the importance of incorporating nutritional interventions into preventive and therapeutic strategies for GEP-NEN patients. Future research should further clarify these associations and develop personalized nutritional management protocols to improve patient prognosis and quality of life. Acronyms adopted in the text and tables: AOR: adjusted odd ratio, BIA: Bioelectrical Impedance Analysis, BMI: Body Mass Index, CI: confidence interval, CLARINET: Controlled Study of Lanreotide Antiproliferative Response in Neuroendocrine Tumor, FLI: fatty liver index, GEP: gastroenteropancreatic, GLIM: global leadership into malnutrition, HR: hazard ratio, MS: metabolic syndrome, MUST: malabsorption universal screening tool, NEC: neuroendocrine carcinoma, NENs: Neuroendocrine neoplasms, NETs: Neuroendocrine tumors, NRS: Nutritional Risk Screening, OR: odd ratio, OS: overall survival, PFS: progression-free survival, RR: risk ratio, SGA: Subjective Global Assessment, T2DM: type 2 diabetes mellitus, VAI: visceral adiposity index, WD: well-differentiated.</abstract><cop>Germany</cop><pmid>39653986</pmid><doi>10.1007/s11154-024-09937-2</doi><orcidid>https://orcid.org/0000-0002-9324-3946</orcidid><orcidid>https://orcid.org/0009-0001-8339-5591</orcidid><orcidid>https://orcid.org/0000-0003-2478-683X</orcidid><orcidid>https://orcid.org/0000-0002-1512-8926</orcidid><orcidid>https://orcid.org/0009-0002-6045-2992</orcidid><orcidid>https://orcid.org/0000-0001-9054-456X</orcidid><orcidid>https://orcid.org/0000-0003-3516-8471</orcidid><orcidid>https://orcid.org/0000-0002-7427-1431</orcidid><orcidid>https://orcid.org/0000-0003-4049-2559</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1389-9155
ispartof Reviews in endocrine & metabolic disorders, 2024-12
issn 1389-9155
1573-2606
1573-2606
language eng
recordid cdi_proquest_miscellaneous_3146609409
source SpringerLink Journals
title Nutritional status and gastroenteropancreatic neuroendocrine neoplasms: lights and shadows with a clinical guide from the NIKE Group
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-16T03%3A04%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nutritional%20status%20and%20gastroenteropancreatic%20neuroendocrine%20neoplasms:%20lights%20and%20shadows%20with%20a%20clinical%20guide%20from%20the%20NIKE%20Group&rft.jtitle=Reviews%20in%20endocrine%20&%20metabolic%20disorders&rft.au=Vitale,%20Giovanni&rft.aucorp=Nike%20Group&rft.date=2024-12-09&rft.issn=1389-9155&rft.eissn=1573-2606&rft_id=info:doi/10.1007/s11154-024-09937-2&rft_dat=%3Cproquest_cross%3E3146609409%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3146609409&rft_id=info:pmid/39653986&rfr_iscdi=true